myelofibrosis – Medxy AI

KT-253: A Novel MDM2 Degrader Targeting Malignant Stem Cells in Myelofibrosis

By MedXY 10/14/2026

KT-253, a selective MDM2 protein degrader, shows potent elimination of malignant myelofibrosis stem/progenitor cells by enhancing p53 pathway activation, outperforming current MDM2 inhibitors and offering a promising therapeutic advance.

Clinical Updates Hematology-Oncology news

Fibrocytes and Therapeutic Potential of Pitavastatin in JAK2V617F-Mutated Myelofibrosis: A Comprehensive Review

By MedXY 09/29/2026

This review elucidates fibrocytes' critical role in JAK2V617F-mutated myelofibrosis pathogenesis and evaluates pitavastatin’s promising therapeutic effects in reversing marrow fibrosis and anemia, integrating mechanistic insights and preclinical evidence.

Hematology-Oncology news

FAP-1 Deficiency: A Novel Mechanistic Link to Impaired Megakaryocyte Maturation, Platelet Dysfunction, and Myelofibrosis-like Disease

By MedXY 09/16/2026

Loss of FAP-1 disrupts megakaryocyte membrane development and platelet function through aberrant Src activation, leading to myelofibrosis-like pathology with potential therapeutic targeting by Src inhibition.

Hematology-Oncology news

Final Phase II Trial Results: Azacitidine plus Ruxolitinib Shows Promise in Myelofibrosis Management

By MedXY 09/03/2026

The combination therapy of azacitidine and ruxolitinib demonstrates a 72% overall response rate in myelofibrosis patients, highlighting enhanced efficacy beyond JAK2 inhibitor monotherapy in a phase II clinical trial.

Hematology-Oncology news

Advancing Diagnosis in Myeloproliferative Neoplasms: Non-invasive Multiparametric Profiling of ET, Premyeloﬁbrosis, and Overt Myeloﬁbrosis

By MedXY 08/07/2026

This study evaluates non-invasive biomarkers to differentiate essential thrombocythemia, premyelofibrosis, and overt myelofibrosis, revealing distinct inflammatory and immune profiles and supporting a disease continuum model.